ZERIA PHARMCEUTICAL CO., LTD. Logo

ZERIA PHARMCEUTICAL CO., LTD.

Develops and distributes prescription & consumer healthcare products in Europe and Asia.

4559 | T

Overview

Corporate Details

ISIN(s):
JP3428850006
LEI:
Country:
Japan
Address:
中央区日本橋小舟町10番11号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zeria Pharmaceutical Co., Ltd. is a comprehensive healthcare company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates through two primary business segments: Ethical Pharmaceuticals (prescription drugs) and Consumer Healthcare (over-the-counter products). Its consumer product portfolio includes nutritional health drugs, remedies for gastrointestinal diseases, cold remedies, and ophthalmic solutions. Zeria actively expands its R&D pipeline by in-licensing and developing drugs with established sales records in overseas markets, distributing its products internationally across Europe and Asia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 02:00
Registration Form
確認書
Japanese 8.4 KB
2025-11-07 02:00
Interim Report
半期報告書-第72期(2025/04/01-2026/03/31)
Japanese 202.1 KB
2025-07-03 07:19
Post-Annual General Meeting Information
臨時報告書
Japanese 23.2 KB
2025-06-26 03:01
Regulatory News Service
内部統制報告書-第71期(2024/04/01-2025/03/31)
Japanese 24.9 KB
2025-06-26 03:00
Regulatory News Service
確認書
Japanese 8.4 KB
2025-06-26 03:00
Annual Report
有価証券報告書-第71期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2024-11-08 02:01
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-11-08 02:00
Interim Report
半期報告書-第71期(2024/04/01-2025/03/31)
Japanese 204.2 KB
2024-07-03 03:44
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2024-06-27 07:11
Registration Form
確認書
Japanese 8.4 KB
2024-06-27 07:09
Governance Information
内部統制報告書-第70期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-27 07:07
Annual Report
有価証券報告書-第70期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-02-05 06:04
Quarterly Report
四半期報告書-第70期第3四半期(2023/10/01-2023/12/31)
Japanese 168.4 KB
2024-02-05 06:04
Report Publication Announcement
確認書
Japanese 8.3 KB
2023-11-06 07:10
Report Publication Announcement
確認書
Japanese 8.3 KB

Automate Your Workflow. Get a real-time feed of all ZERIA PHARMCEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ZERIA PHARMCEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ZERIA PHARMCEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.